Drawing for HAEMA BLUT UND PLASMA

USPTO serial 79411781

HAEMA BLUT UND PLASMA

Reviewed by CopyMark Law Group

Reg. 8105646Status 700Registered
Filing date
Status date
Registration date
Jan 20, 2026
Examiner
ABID, NABEELA
Law office
FILE REPOSITORY (FRANCONIA)

What this means

Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.

Status 700: Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six.

Need help with HAEMA BLUT UND PLASMA?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Deborah L. Shapiro

Deborah L. Shapiro Moses & Singer LLP405 Lexington AvenueThe Chrysler BuildingNew York, NY 10174

Goods and services

ClassDescriptionStatusFirst use
005Medicines, in particular medicines made from blood components, fractions and preparations, with said medicines being for the treatment of diseases and disorders of the blood; blood components, fractions and preparations, namely, blood for medical purposes, blood plasma, and blood substitutes for human use; blood components, fractions and preparations for injection, namely, blood for medical purposes, blood plasma, and blood substitutes for human use; blood components, fractions and preparations for automatic transplantation, namely, blood for medical purposes, blood plasma, and blood substitutes for human use; blood components, fractions and preparations for transfusion, namely, blood for medical purposes, blood plasma, and blood substitutes for human use; blood components, fractions and preparations for immunotherapy, namely, blood for medical purposes, blood plasma, and blood substitutes for human use; blood components, fractions and preparations for autologous transfusion, namely, blood for medical purposes, blood plasma, and blood substitutes for human use; blood, blood fractions and blood components for medical, therapeutic and prophylactic purposes, namely, blood for medical purposes, blood plasma, and blood substitutes for human use; blood plasma; cells for medical use, namely, blood cell preparations; health care substances and preparations, in particular for haematology, namely, pharmaceuticals for the treatment of blood diseases and disorders, blood for medical purposes, blood plasma, and blood substitutes for human use; finished medical products, namely, blood for human use and blood plasma; preparations for medical purposes, in particular haematology preparations, namely, pharmaceuticals for the treatment of blood diseases and disorders, blood for medical purposes, blood plasma, and blood substitutes for human use; immunotherapeutic and immunoprophylactic preparations, namely, pharmaceuticals for treating immunological diseases and disorders; living cells for medical purposes, namely, leukocyte preparations of white blood cells; Living cells and cell fragments for medical purposes, namely, platelet and red blood cell concentrates; blood plasma, namely, quarantine plasma and fractionated plasma; clinical medical reagents for processing human blood and blood components for use in blood transfusions and for extracorporeal blood processing stored in bags, bottles, syringes and similar containers for storing substances such as these for medical purposes; pharmaceutical products and haematology preparations for the treatment of blood and blood components, in particular infusion and transfusion solutions in the nature of blood, blood plasma, and blood substitutes for human use and pharmaceuticals for the treatment of blood diseases and disorders; pharmaceutical blood plasma preparations for the treatment of blood diseases and disorders; pharmaceutical blood preparations for the treatment of blood diseases and disorders; pharmaceutical blood products, namely, pharmaceuticals for the treatment of blood diseases and disorders; cell material for autotransplantation and autotransfusion, namely, cells for medical use; cell material for transplantation and transfusion, namely, cells for medical use; cell material for medical, therapeutic and prophylactic purposes, namely, cells for medical or clinical useACTIVE—
035Updating and maintenance of blood donor data in computer databasesACTIVE—
042Technical provision and support for data processing systems, namely, providing technology information in the field of data processing and technical support services in the nature of troubleshooting computer software problems in connection with data processing; providing temporary use of online non-downloadable computer software for accessing patient treatment databases and donor databases; providing technological and scientific information about scientific laboratories services and blood banks, in particular medical laboratories; providing scientific information derived from analysis of medical diagnostic results; blood analysis services for scientific research purposes; scientific laboratory services; chemical laboratories and medical research laboratories; scientific research in the field of physics; chemistry services, namely, chemical analysis, chemical laboratories; chemical analysis; scientific testing services, namely, blood testing for scientific research purposes; blood testing for scientific research purposes, with said testing entailing filtration, separation and centrifugation of blood; laboratory trials, namely, medical and scientific research in the nature of conducting clinical trials for others; development and further development of data processing computer software and hardware in the field of laboratory medicine and blood and plasma collection; database development services, namely, creation of medical databases in digital form; scientific and medical research in the medical and pharmaceutical fields; scientific and medical research in the field of chemistry and biology; development and establishment of testing specifications and procedures for the medical industry, namely, development of medical equipment procedures and test procedures, donation procedures and medical instrument proceduresACTIVE—
044Medical analysis services and medical consultancy all relating to the treatment of persons in connection with blood and plasma donation; medical consultancy in relation to transfusion medicine; pharmacy advice in the nature of pharmaceutical advice; providing of medical information in relation to blood donation centres; providing of medical and pharmaceutical support being medical assistance and pharmaceutical advice via telephone; medical services in the field of blood fractionation and treatment; medical services in the field of blood sampling and collection; blood testing services being medical analysis services for diagnostic and treatment purposes provided by medical laboratories; medical assistance; blood bank services; blood donation centres being health center services; blood extraction stations being health center services; medical services in the field of immunotherapy; medical consultancy in relation to transfusion medicine and clinic hygiene; medical transfusion consultancy in clinics, in particular medical consultancy by doctors administering transfusions; medical transfusion testing for diagnostic or treatment purposes; providing medical diagnostic information through medical results; medical diagnostic services within the framework of conducting medical examinations; conducting of blood donation, platelet donation, erythrocyte donation, whole blood donation, plasma donation, and autologous donation, all in the nature of blood bank services; medical examination services; execution of clinical examination services, namely, medical examination services; dietetic advisory services; medical services in the nature of providing medical opinions; health counselling; medical services in the field of transfusion and transplantation of blood and blood components; medical services; providing medical information relating to the use of medical equipment, instruments and apparatus for medical purposes; medical services relating to packed red blood cell banks; medical services relating to platelet concentrate banks; medical services relating to leukocyte banks; medical services relating to blood plasma banks, and blood for medical and diagnostic purposes; blood component banks being blood bank services; health assessment services, namely, providing a database in the field of blood donor medical information based on collected data and information all for treatment and diagnostic purposes; extraction of stem cells being medical services relating to the removal, treatment and processing of stem cellsACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Aug 13, 2026FINOFINAL DECISION TRANSACTION PROCESSED BY IB—
Jul 27, 2026FICSFINAL DISPOSITION NOTICE SENT TO IB—
Jul 27, 2026FIMPFINAL DISPOSITION PROCESSED—
May 28, 2026OPNXNOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB—
May 11, 2026OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB—
May 11, 2026OPNRNOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB—
Apr 20, 2026FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
Jan 20, 2026NRCCNOTICE OF REGISTRATION CONFIRMATION EMAILED—
Jan 20, 2026R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Dec 11, 2025GPNXNOTIFICATION PROCESSED BY IB—
Dec 2, 2025NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Dec 2, 2025PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Nov 26, 2025OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB—
Nov 26, 2025NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Nov 25, 2025OP2RNOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB—
Oct 31, 2025CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Oct 31, 2025XAECEXAMINER'S AMENDMENT ENTERED—
Oct 31, 2025GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Oct 31, 2025GNEAEXAMINERS AMENDMENT E-MAILED—
Oct 31, 2025CNEAEXAMINERS AMENDMENT -WRITTEN—
Oct 30, 2025TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Oct 30, 2025CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Oct 30, 2025TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Sep 27, 2025RFNTREFUSAL PROCESSED BY IB—
Sep 5, 2025RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Sep 5, 2025RFRRREFUSAL PROCESSED BY MPU—
Aug 1, 2025RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Jul 31, 2025CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jul 31, 2025DOCKASSIGNED TO EXAMINER—
Jul 30, 2025MAFRAPPLICATION FILING RECEIPT MAILED—
Jul 30, 2025NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Apr 18, 2025ADCHCHANGE OF NAME/ADDRESS REC'D FROM IB—
Dec 12, 2024REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance